latest tirzepatide news

latest tirzepatide news FDA Says Compounded Must Exit the Market Lilly, Novo Fight Weight Loss

Name: latest tirzepatide news FDA Says Compounded Must Exit the Market Lilly, Novo Fight Weight Loss
Brand: canberracompanytax.com
SKU: 20400165350
Price: 21.35 USD
Availability: InStock
Rating: 4.6696 (26 reviews)

SKU: 20400165350

4.7

EUR21.35 EUR71.35

Pay in 4 interest-free payments of $5.34 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Description

The study showed a 13% reduction in major adverse cardiovascular events (MACE), a composite endpoint for cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in patients treated with liraglutide compared with placebo at a mean follow-up of 3.8 years (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.780.97) and a significant reduction in cardiovascular death (HR 0.78, 95% CI 0.660.93)